These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 10562412

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
    Poli-Scaife S, Attias R, Dansette PM, Mansuy D.
    Biochemistry; 1997 Oct 21; 36(42):12672-82. PubMed ID: 9335524
    [Abstract] [Full Text] [Related]

  • 8. Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
    Darbyshire JF, Iyer KR, Grogan J, Korzekwa KR, Trager WF.
    Drug Metab Dispos; 1996 Sep 21; 24(9):1038-45. PubMed ID: 8886617
    [Abstract] [Full Text] [Related]

  • 9. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
    Kunze KL, Wienkers LC, Thummel KE, Trager WF.
    Drug Metab Dispos; 1996 Apr 21; 24(4):414-21. PubMed ID: 8801056
    [Abstract] [Full Text] [Related]

  • 10. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
    Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS, Smith DA.
    Drug Metab Dispos; 1996 Feb 21; 24(2):260-6. PubMed ID: 8742240
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin.
    Kunze KL, Eddy AC, Gibaldi M, Trager WF.
    Chirality; 1991 Feb 21; 3(1):24-9. PubMed ID: 2039681
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H, Inoue K, Shimada T.
    Xenobiotica; 1998 Feb 21; 28(2):103-15. PubMed ID: 9522436
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T, Fukuda T, Ikeda M, Imaoka S, Hiroi T, Funae Y, Azuma J.
    Pharmacogenomics J; 2001 Feb 21; 1(4):288-92. PubMed ID: 11908770
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
    Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.
    Drug Metab Dispos; 2000 Aug 21; 28(8):994-1002. PubMed ID: 10901712
    [Abstract] [Full Text] [Related]

  • 19. Microbial models of mammalian metabolism: production of novel alpha-diketone metabolites of warfarin and phenprocoumon using Aspergillus niger.
    Rizzo JD, Davis PJ.
    Xenobiotica; 1988 Dec 21; 18(12):1425-37. PubMed ID: 3245234
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.